Key Takeaways
- The Supreme Court has questioned the Centre's decision to cap trade margins at 30% for non-scheduled cancer drugs
- The proposed cap is expected to reduce the financial burden on patients, particularly those requiring expensive cancer treatments
- The court's concerns about the availability of price-controlled medicines highlight the need for a more comprehensive approach to regulating medicine prices in India
What the 30% cap changes for patients
The Supreme Court has questioned why the benefit of price regulation should be confined to cancer drugs and not extended to other essential medicines and medical products.
The court expressed concern over stark disparities between the price to retailer and the maximum retail price of certain medicines, with mark-ups in some instances soaring to 1,000%.
Who is affected by the new slab
Patient groups and medical professionals have long argued that high trade margins on essential medicines and medical products place an enormous financial burden on patients.
The proposed 30% trade-margin cap would cover both patented and non-patented cancer medicines, with an expert committee tasked with identifying the drugs to be brought within its ambit.
By the numbers
- 30% trade-margin cap proposed for non-scheduled cancer drugs
- 1,000% mark-up on some medicines
- โน2,500 crore estimated annual savings for patients
- 20% to 70% reduction in MRP of anti-cancer drugs expected
The Centre's response
The Centre informed the Supreme Court that it had decided to cap trade margins at 30% for non-scheduled cancer drugs, but the court questioned why the benefit of such price regulation should not be extended to other essential medicines and medical products.
Additional Solicitor General Aishwarya Bhati argued that low-value products often required higher margins to remain commercially viable for retailers, and that excessive regulation could discourage retailers from stocking such medicines.
The court's concerns
Justice Sandeep Mehta drew attention to steep markups on medical devices and consumables, pointing out that an India-made cardiac stent costing around โน5,000 was being sold by hospitals for more than โน25,000.
The court observed that ensuring the availability of price-controlled medicines was the government's responsibility, and that the actual dispute was over which medicines should be on the DPCO-controlled list and which should not.
Next steps
The Centre has been given until October 27 to work out the modalities for capping medicine prices, when the matter will be heard next.
Implications for patients in India
The proposed 30% trade-margin cap is expected to reduce the financial burden on patients, particularly those requiring expensive cancer treatments.
However, the court's concerns about the availability of price-controlled medicines highlight the need for a more comprehensive approach to regulating medicine prices in India.
Read also: Insulin discovery and its impact on diabetes treatment
Read also: Russia lab death investigation updates
Expert perspective
Pharmaceutical experts argue that a uniform cap on trade margins could lead to unintended consequences, such as reduced availability of certain medicines in rural areas.
Others argue that the government should take a more proactive role in regulating medicine prices, to ensure that patients have access to affordable and essential medicines.
What to watch next
The Centre's response to the court's concerns, and the outcome of the next hearing on October 27, will be crucial in determining the future of medicine price regulation in India.
Background and history of medicine price regulation
The Drugs (Prices Control) Order (DPCO), 2013, is the primary legislation governing medicine price regulation in India.
The DPCO sets a ceiling price for medicines listed in Schedule I, and allows manufacturers to determine the initial launch price for non-scheduled formulations.
Impact on the pharmaceutical industry
The proposed 30% trade-margin cap is expected to have a significant impact on the pharmaceutical industry, with potential consequences for manufacturers, distributors, and retailers.
The industry has argued that excessive regulation could lead to reduced investment in research and development, and decreased availability of certain medicines.
Frequently Asked Questions
What is the proposed trade-margin cap for non-scheduled cancer drugs?
The proposed trade-margin cap is 30%.
Why has the Supreme Court questioned the Centre's decision?
The Supreme Court has questioned the Centre's decision because it wants to know why the benefit of price regulation should not be extended to other essential medicines and medical products.
What are the implications of the proposed cap for patients in India?
The proposed cap is expected to reduce the financial burden on patients, particularly those requiring expensive cancer treatments.
